#METABOLOMICS WORKBENCH borjalanzon_20210402_054551 DATATRACK_ID:2556 STUDY_ID:ST001824 ANALYSIS_ID:AN002960 PROJECT_ID:PR001153
VERSION             	1
CREATED_ON             	May 11, 2021, 11:44 am
#PROJECT
PR:PROJECT_TITLE                 	Metabolomic and lipidomic profiles of CKD in obese patients in serum and urine
PR:PROJECT_TITLE                 	(part 1 of 3)
PR:PROJECT_TYPE                  	Human nephropathy in CKD obese patients
PR:PROJECT_SUMMARY               	Obesity is a global pandemic with an increase prevalence over the years. This
PR:PROJECT_SUMMARY               	condition elevates the risk of developing cardiovascular diseases, hypertension
PR:PROJECT_SUMMARY               	and renal pathologies, like chronic kidney disease (CKD). In the present study,
PR:PROJECT_SUMMARY               	the metabolomic and the lipidomic profiles of CKD obese patients were analyzed
PR:PROJECT_SUMMARY               	comparing with obese subjects without CKD. Subsequently, CKD obese patients
PR:PROJECT_SUMMARY               	underwent bariatric surgery and the effect of surgery in the CKD progression of
PR:PROJECT_SUMMARY               	these subjects was evaluated. Serum and urine were measured by LC-MS and GC-HRAM
PR:PROJECT_SUMMARY               	equipment.
PR:INSTITUTE                     	University Rey Juan Carlos
PR:DEPARTMENT                    	Basics Science of Health
PR:LAST_NAME                     	Lanzon
PR:FIRST_NAME                    	Borja
PR:ADDRESS                       	Avenida de Atenas S/N
PR:EMAIL                         	borja.lanzon@urjc.es
PR:PHONE                         	663692554
#STUDY
ST:STUDY_TITLE                   	Metabolomic and lipidomic profiles of CKD in obese patients in serum and urine
ST:STUDY_TITLE                   	(part 1 of 3)
ST:STUDY_TYPE                    	Human nephropathy in CKD obese patients
ST:STUDY_SUMMARY                 	Obesity is a global pandemic with an increase prevalence over the years. This
ST:STUDY_SUMMARY                 	condition elevates the risk of developing cardiovascular diseases, hypertension
ST:STUDY_SUMMARY                 	and renal pathologies, like chronic kidney disease (CKD). In the present study,
ST:STUDY_SUMMARY                 	the metabolomic and the lipidomic profiles of CKD obese patients were analyzed
ST:STUDY_SUMMARY                 	comparing with obese subjects without CKD. Subsequently, CKD obese patients
ST:STUDY_SUMMARY                 	underwent bariatric surgery and the effect of surgery in the CKD progression of
ST:STUDY_SUMMARY                 	these subjects was evaluated. Serum and urine were measured by LC-MS and GC-HRAM
ST:STUDY_SUMMARY                 	equipment.
ST:INSTITUTE                     	University Rey Juan Carlos
ST:DEPARTMENT                    	Basics Science of Health
ST:LAST_NAME                     	Lanzon
ST:FIRST_NAME                    	Borja
ST:ADDRESS                       	Avenida de Atenas S/N
ST:EMAIL                         	borja.lanzon@urjc.es
ST:PHONE                         	663692554
ST:NUM_GROUPS                    	3
ST:TOTAL_SUBJECTS                	36
ST:STUDY_COMMENTS                	Serum LC-MS data: part 1 of 3. Samples were analyzed per duplicated.
#SUBJECT
SU:SUBJECT_TYPE                  	Human
SU:SUBJECT_SPECIES               	Homo sapiens
SU:TAXONOMY_ID                   	9606
SU:AGE_OR_AGE_RANGE              	53 ± 15
SU:WEIGHT_OR_WEIGHT_RANGE        	116 ± 25
SU:GENDER                        	Male and female
#FACTORS
#SUBJECT_SAMPLE_FACTORS:         	SUBJECT(optional)[tab]SAMPLE[tab]FACTORS(NAME:VALUE pairs separated by |)[tab]Raw file names and additional sample data
SUBJECT_SAMPLE_FACTORS           	-	O1_1	Genotype:O	RAW_FILE_NAME=O1_1
SUBJECT_SAMPLE_FACTORS           	-	O1_2	Genotype:O	RAW_FILE_NAME=O1_2
SUBJECT_SAMPLE_FACTORS           	-	O2_1	Genotype:O	RAW_FILE_NAME=O2_1
SUBJECT_SAMPLE_FACTORS           	-	O2_2	Genotype:O	RAW_FILE_NAME=O2_2
SUBJECT_SAMPLE_FACTORS           	-	O3_1	Genotype:O	RAW_FILE_NAME=O3_1
SUBJECT_SAMPLE_FACTORS           	-	O3_2	Genotype:O	RAW_FILE_NAME=O3_2
SUBJECT_SAMPLE_FACTORS           	-	O4_1	Genotype:O	RAW_FILE_NAME=O4_1
SUBJECT_SAMPLE_FACTORS           	-	O4_2	Genotype:O	RAW_FILE_NAME=O4_2
SUBJECT_SAMPLE_FACTORS           	-	O5_1	Genotype:O	RAW_FILE_NAME=O5_1
SUBJECT_SAMPLE_FACTORS           	-	O5_2	Genotype:O	RAW_FILE_NAME=O5_2
SUBJECT_SAMPLE_FACTORS           	-	O6_1	Genotype:O	RAW_FILE_NAME=O6_1
SUBJECT_SAMPLE_FACTORS           	-	O6_2	Genotype:O	RAW_FILE_NAME=O6_2
SUBJECT_SAMPLE_FACTORS           	-	O7_1	Genotype:O	RAW_FILE_NAME=O7_1
SUBJECT_SAMPLE_FACTORS           	-	O7_2	Genotype:O	RAW_FILE_NAME=O7_2
SUBJECT_SAMPLE_FACTORS           	-	O8_1	Genotype:O	RAW_FILE_NAME=O8_1
SUBJECT_SAMPLE_FACTORS           	-	O8_2	Genotype:O	RAW_FILE_NAME=O8_2
SUBJECT_SAMPLE_FACTORS           	-	O9_1	Genotype:O	RAW_FILE_NAME=O9_1
SUBJECT_SAMPLE_FACTORS           	-	O9_2	Genotype:O	RAW_FILE_NAME=O9_2
SUBJECT_SAMPLE_FACTORS           	-	O10_1	Genotype:O	RAW_FILE_NAME=O10_1
SUBJECT_SAMPLE_FACTORS           	-	O10_2	Genotype:O	RAW_FILE_NAME=O10_2
SUBJECT_SAMPLE_FACTORS           	-	O11_1	Genotype:O	RAW_FILE_NAME=O11_1
SUBJECT_SAMPLE_FACTORS           	-	O11_2	Genotype:O	RAW_FILE_NAME=O11_2
SUBJECT_SAMPLE_FACTORS           	-	O12_1	Genotype:O	RAW_FILE_NAME=O12_1
SUBJECT_SAMPLE_FACTORS           	-	O12_2	Genotype:O	RAW_FILE_NAME=O12_2
SUBJECT_SAMPLE_FACTORS           	-	O13_1	Genotype:O	RAW_FILE_NAME=O13_1
SUBJECT_SAMPLE_FACTORS           	-	O13_2	Genotype:O	RAW_FILE_NAME=O13_2
SUBJECT_SAMPLE_FACTORS           	-	O14_1	Genotype:O	RAW_FILE_NAME=O14_1
SUBJECT_SAMPLE_FACTORS           	-	O14_2	Genotype:O	RAW_FILE_NAME=O14_2
SUBJECT_SAMPLE_FACTORS           	-	OD1_1	Genotype:OD	RAW_FILE_NAME=OD1_1
SUBJECT_SAMPLE_FACTORS           	-	OD1_2	Genotype:OD	RAW_FILE_NAME=OD1_2
SUBJECT_SAMPLE_FACTORS           	-	OD2_1	Genotype:OD	RAW_FILE_NAME=OD2_1
SUBJECT_SAMPLE_FACTORS           	-	OD2_2	Genotype:OD	RAW_FILE_NAME=OD2_2
SUBJECT_SAMPLE_FACTORS           	-	OD3_1	Genotype:OD	RAW_FILE_NAME=OD3_1
SUBJECT_SAMPLE_FACTORS           	-	OD3_2	Genotype:OD	RAW_FILE_NAME=OD3_2
SUBJECT_SAMPLE_FACTORS           	-	OD4_1	Genotype:OD	RAW_FILE_NAME=OD4_1
SUBJECT_SAMPLE_FACTORS           	-	OD4_2	Genotype:OD	RAW_FILE_NAME=OD4_2
SUBJECT_SAMPLE_FACTORS           	-	OD5_1	Genotype:OD	RAW_FILE_NAME=OD5_1
SUBJECT_SAMPLE_FACTORS           	-	OD5_2	Genotype:OD	RAW_FILE_NAME=OD5_2
SUBJECT_SAMPLE_FACTORS           	-	OD6_1	Genotype:OD	RAW_FILE_NAME=OD6_1
SUBJECT_SAMPLE_FACTORS           	-	OD6_2	Genotype:OD	RAW_FILE_NAME=OD6_2
SUBJECT_SAMPLE_FACTORS           	-	OD7_1	Genotype:OD	RAW_FILE_NAME=OD7_1
SUBJECT_SAMPLE_FACTORS           	-	OD7_2	Genotype:OD	RAW_FILE_NAME=OD7_2
SUBJECT_SAMPLE_FACTORS           	-	OD8_1	Genotype:OD	RAW_FILE_NAME=OD8_1
SUBJECT_SAMPLE_FACTORS           	-	OD8_2	Genotype:OD	RAW_FILE_NAME=OD8_2
SUBJECT_SAMPLE_FACTORS           	-	OD9_1	Genotype:OD	RAW_FILE_NAME=OD9_1
SUBJECT_SAMPLE_FACTORS           	-	OD9_2	Genotype:OD	RAW_FILE_NAME=OD9_2
SUBJECT_SAMPLE_FACTORS           	-	OD10_1	Genotype:OD	RAW_FILE_NAME=OD10_1
SUBJECT_SAMPLE_FACTORS           	-	OD10_2	Genotype:OD	RAW_FILE_NAME=OD10_2
SUBJECT_SAMPLE_FACTORS           	-	OD11_1	Genotype:OD	RAW_FILE_NAME=OD11_1
SUBJECT_SAMPLE_FACTORS           	-	OD11_2	Genotype:OD	RAW_FILE_NAME=OD11_2
SUBJECT_SAMPLE_FACTORS           	-	ODBS1_1	Genotype:ODBS	RAW_FILE_NAME=ODBS1_1
SUBJECT_SAMPLE_FACTORS           	-	ODBS1_2	Genotype:ODBS	RAW_FILE_NAME=ODBS1_2
SUBJECT_SAMPLE_FACTORS           	-	ODBS2_1	Genotype:ODBS	RAW_FILE_NAME=ODBS2_1
SUBJECT_SAMPLE_FACTORS           	-	ODBS2_2	Genotype:ODBS	RAW_FILE_NAME=ODBS2_2
SUBJECT_SAMPLE_FACTORS           	-	ODBS3_1	Genotype:ODBS	RAW_FILE_NAME=ODBS3_1
SUBJECT_SAMPLE_FACTORS           	-	ODBS3_2	Genotype:ODBS	RAW_FILE_NAME=ODBS3_2
SUBJECT_SAMPLE_FACTORS           	-	ODBS4_1	Genotype:ODBS	RAW_FILE_NAME=ODBS4_1
SUBJECT_SAMPLE_FACTORS           	-	ODBS4_2	Genotype:ODBS	RAW_FILE_NAME=ODBS4_2
SUBJECT_SAMPLE_FACTORS           	-	ODBS5_1	Genotype:ODBS	RAW_FILE_NAME=ODBS5_1
SUBJECT_SAMPLE_FACTORS           	-	ODBS5_2	Genotype:ODBS	RAW_FILE_NAME=ODBS5_2
SUBJECT_SAMPLE_FACTORS           	-	ODBS6_1	Genotype:ODBS	RAW_FILE_NAME=ODBS6_1
SUBJECT_SAMPLE_FACTORS           	-	ODBS6_2	Genotype:ODBS	RAW_FILE_NAME=ODBS6_2
SUBJECT_SAMPLE_FACTORS           	-	ODBS7_1	Genotype:ODBS	RAW_FILE_NAME=ODBS7_1
SUBJECT_SAMPLE_FACTORS           	-	ODBS7_2	Genotype:ODBS	RAW_FILE_NAME=ODBS7_2
SUBJECT_SAMPLE_FACTORS           	-	ODBS8_1	Genotype:ODBS	RAW_FILE_NAME=ODBS8_1
SUBJECT_SAMPLE_FACTORS           	-	ODBS8_2	Genotype:ODBS	RAW_FILE_NAME=ODBS8_2
SUBJECT_SAMPLE_FACTORS           	-	ODBS9_1	Genotype:ODBS	RAW_FILE_NAME=ODBS9_1
SUBJECT_SAMPLE_FACTORS           	-	ODBS9_2	Genotype:ODBS	RAW_FILE_NAME=ODBS9_2
SUBJECT_SAMPLE_FACTORS           	-	ODBS10_1	Genotype:ODBS	RAW_FILE_NAME=ODBS10_1
SUBJECT_SAMPLE_FACTORS           	-	ODBS10_2	Genotype:ODBS	RAW_FILE_NAME=ODBS10_2
SUBJECT_SAMPLE_FACTORS           	-	ODBS11_1	Genotype:ODBS	RAW_FILE_NAME=ODBS11_1
SUBJECT_SAMPLE_FACTORS           	-	ODBS11_2	Genotype:ODBS	RAW_FILE_NAME=ODBS11_2
SUBJECT_SAMPLE_FACTORS           	-	QC1	Genotype:QC	RAW_FILE_NAME=QC1
SUBJECT_SAMPLE_FACTORS           	-	QC1_ext	Genotype:QC	RAW_FILE_NAME=QC1_ext
SUBJECT_SAMPLE_FACTORS           	-	QC2	Genotype:QC	RAW_FILE_NAME=QC2
SUBJECT_SAMPLE_FACTORS           	-	QC2_ext	Genotype:QC	RAW_FILE_NAME=QC2_ext
#COLLECTION
CO:COLLECTION_SUMMARY            	Serum samples were collected for CKD obese patients (OD), obese patients without
CO:COLLECTION_SUMMARY            	CKD (O) and CKD obese patients who underwent bariatric surgery (OD BS). Samples
CO:COLLECTION_SUMMARY            	were centrifuged (3500 rpm, 15 min at 4 °C), aliquoted and stored at -80 °C
CO:COLLECTION_SUMMARY            	until extraction.
CO:SAMPLE_TYPE                   	Blood (serum)
CO:STORAGE_CONDITIONS            	-80℃
#TREATMENT
TR:TREATMENT_SUMMARY             	10 µl of each serum sample were added to 10 µl of 0.9% NaCl and 120 µl of
TR:TREATMENT_SUMMARY             	CHCl3: MeOH (2:1, v/v) containing a 2.5 ppm solution of different lipids
TR:TREATMENT_SUMMARY             	standards. Lipids were extracted with CHCl3: MeOH (2:1, v/v).
#SAMPLEPREP
SP:SAMPLEPREP_SUMMARY            	10 µl of each serum sample were added to 10 µl of 0.9% NaCl and 120 µl of
SP:SAMPLEPREP_SUMMARY            	CHCl3: MeOH (2:1, v/v) containing a 2.5 ppm solution of different lipids
SP:SAMPLEPREP_SUMMARY            	standards. Samples were randomized, vortex-mixed and put on ice for 30 min.
SP:SAMPLEPREP_SUMMARY            	After that, samples were centrifuged (9400 g, 3 min, 4 °C). Then, 60 µl of the
SP:SAMPLEPREP_SUMMARY            	lower layer of each sample was transferred to a glass vial with an insert and 60
SP:SAMPLEPREP_SUMMARY            	µl of CHCl3: MeOH (2:1, v/v) was added. Samples were stored at -80 °C until
SP:SAMPLEPREP_SUMMARY            	LC-MS analysis.
SP:PROCESSING_STORAGE_CONDITIONS 	On ice
SP:EXTRACT_STORAGE               	-80℃
#CHROMATOGRAPHY
CH:CHROMATOGRAPHY_SUMMARY        	An ultra-high-performance liquid chromatography electrospray ionization
CH:CHROMATOGRAPHY_SUMMARY        	quadrupole time-of-flight (UHPLC-ESI-Q-TOF-MS) were used to analyze the samples
CH:CHROMATOGRAPHY_SUMMARY        	on positive ionization mode. Samples were analyzed by duplicate. UHPLC system
CH:CHROMATOGRAPHY_SUMMARY        	was an Agilent Infinity 1290 provided by Agilent Technologies (Santa Clara, CA,
CH:CHROMATOGRAPHY_SUMMARY        	USA) equipped with a multisampler (kept at -10 °C). Needle wash solutions were
CH:CHROMATOGRAPHY_SUMMARY        	performed with 10% DCM in MeOH and ACN:MeOH:IPA:H2O (1:1:1:1, v/v/v/v), and 0.1%
CH:CHROMATOGRAPHY_SUMMARY        	of HCOOH after each injection for 7.5 s. System were equipped with a column
CH:CHROMATOGRAPHY_SUMMARY        	thermostat (maintained at 50 °C) and a quaternary solvent manager. An ACQUITY
CH:CHROMATOGRAPHY_SUMMARY        	UPLC BEH C18 column was used for separations (2.1 mm x 100 mm, particle size 1.7
CH:CHROMATOGRAPHY_SUMMARY        	μm) purchased at Waters (Milford, CT, USA). Injection volume was 1 μl and flow
CH:CHROMATOGRAPHY_SUMMARY        	rate was established at 0.4 ml/min. Mobile phases were composed of (A) H2O +
CH:CHROMATOGRAPHY_SUMMARY        	NH4AC 10 mM + 0.1 % HCOOH and (B) ACN: IPA (1:1, v/v) + NH4AC 10 mM + 0.1 %
CH:CHROMATOGRAPHY_SUMMARY        	HCOOH. Gradient was from 0 to 2 min 35-80 % B, 2 min to 7 min 80-100 % B and 7
CH:CHROMATOGRAPHY_SUMMARY        	to 14 min 100 % B. A re-equilibration of 7 min was performed after each run to
CH:CHROMATOGRAPHY_SUMMARY        	bring system to initial conditions (35 % B).
CH:CHROMATOGRAPHY_TYPE           	Reversed phase
CH:INSTRUMENT_NAME               	Agilent Infinity 1290
CH:COLUMN_NAME                   	ACQUITY UPLC BEH C18
CH:FLOW_GRADIENT                 	0 to 2 min 35-80 % B, 2 min to 7 min 80-100 % B and 7 to 14 min 100 % B
CH:FLOW_RATE                     	0.4 ml/min
CH:COLUMN_TEMPERATURE            	50
CH:SOLVENT_A                     	H2O + NH4AC 10 mM + 0.1 % HCOOH
CH:SOLVENT_B                     	ACN: IPA (1:1, v/v) + NH4AC 10 mM + 0.1 % HCOOH
#ANALYSIS
AN:ANALYSIS_TYPE                 	MS
#MS
MS:INSTRUMENT_NAME               	Agilent 6545 Q-TOF
MS:INSTRUMENT_TYPE               	QTOF
MS:MS_TYPE                       	ESI
MS:ION_MODE                      	POSITIVE
MS:MS_COMMENTS                   	Mass Spectrometer was an Agilent 6545 quadrupole time-of-flight (Q-TOF) mounted
MS:MS_COMMENTS                   	with a dual jet stream electrospray (dual ESI) ion source interface. Nitrogen
MS:MS_COMMENTS                   	was obtained from a nitrogen generator (PEAK Scientific, Renfrewshire, Scotland,
MS:MS_COMMENTS                   	UK) as a sheath gas at a flow rate of 11 l/min at 379 °C. As a Collision gas
MS:MS_COMMENTS                   	was used Pure Nitrogen (6.0) from Praxair (Fredericia, Denmark). Capillary
MS:MS_COMMENTS                   	voltage was maintained at 3600 V and nozzle voltage was kept at 1500 V.
MS:MS_COMMENTS                   	Reference mass solution was prepared in consonance with Agilent guidelines,
MS:MS_COMMENTS                   	including ions at m/z 121.0509 and 922.0098. The second nebulizer was used to
MS:MS_COMMENTS                   	introduce the solution in the dual ESI ion source through the isocratic pump at
MS:MS_COMMENTS                   	a constant flow rate of 4 ml/min (split to 1:100 before nebulization).
MS:MS_COMMENTS                   	Acquisition mass range was 100 to 3000 m/z. Instrument used the extended dynamic
MS:MS_COMMENTS                   	range with an estimated resolution of 30.000 FWHM measured at 1521.9715 m/z
MS:MS_COMMENTS                   	(included in tune mixture) when instrument calibration was performed.
MS:CAPILLARY_VOLTAGE             	3600 V
MS:MS_RESULTS_FILE               	ST001824_AN002960_Results.txt	UNITS:Area	Has m/z:Yes	Has RT:Yes	RT units:Minutes
#END